Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

India: DIPP discussion paper on compulsory licensing in the Indian Pharmaceutical sector: An ‘acquired’ afterthought? (Spicy IP)

Lipitor (Atorvastatin) – Brazil: INPI wins the battle against the patent extension for Lipitor (IP tango)

Lovenox (Enoxaparin) – US: DC District Court denies preliminary injunction in generic Lovenox case; Is the juice worth the squeeze for Sanofi to appeal?: Sanofi-Aventis v FDA, Sandoz (FDA Law Blog) (GenericsWeb)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

WSJ reports on the access to drugs debate (Afro-IP)

Special edition of Scientific American offers global biotechnology perspective (Patent Docs)

Reportlinker adds the outlook for pharmaceuticals in the Middle East and North Africa to 2015 (SmartBrief)

India: Minister of Health against increasing life of pharmaceutical patents (Spicy IP)

India: PMO, MNC, CL and Indian IP policy making: Whither representation and transparency? (Spicy IP)

India: DIPP discussion paper on compulsory licensing in the Indian Pharmaceutical sector: An ‘acquired’ afterthought? (Spicy IP)

India: NPPA proposes controlling the price of cancer drugs (Spicy IP)

India: Requiem for a dream? – state of research and development of new drugs in Indian pharma industry (Spicy IP)

US: The Financial Times’ take on gene patenting (Patent Docs)

US: Seattle Biotech companies fight over allegedly similar names: Mirina Corp. v. Marina Biotech (Seattle Trademark Lawyer)

US: Judges ask FDA: What is ‘natural’? (FDA Law Blog)

US: District Court N D Illinois construes claims re method of treating kidney disease: Bone Care v Pentech Pharma (Chicago IP Litigation Blog)

Products

Angiomax (Bivalirudin) – US: Medicines Company files patent infringement complaint against Hospira in response to Para IV challenge (Patent Docs)

Aranesp (Darbepoetin) – EU: ECJ to rule on Aranesp Thursday 2 Sept: Case C-66/09 Kirin Amgen (The SPC Blog)

Baraclude (Entecavir) – India: Natco and Zydus Cadila launch generic versions of Entecavir (Generic Pharmaceuticals and IP)

Fosamax (Alendronate) – Sweden: District Court of Stockholm denies Teva, Arrow and Ratiopharm’s claims that Merck’s Alendronat SPC was invalid (EPLAW)

Gemzar (Gemcitabine) – US: Eli Lilly files patent infringement suit against Sandoz following Para IV challenge (Patent Docs)

Lipitor (Atorvastatin) – Brazil: INPI wins the battle against the patent extension for Lipitor (IP tango)

Lipitor (Atorvastatin) – US: Plaintiff’s prior settlement agreements/licenses concerning its patented drug are discoverable as relevant to secondary considerations and misuse: Pfizer Inc. et al v. Apotex Inc. et al (Docket Report)

Lovenox (Enoxaparin) – US: DC District Court denies preliminary injunction in generic Lovenox case; Is the juice worth the squeeze for Sanofi to appeal?: Sanofi-Aventis v FDA, Sandoz (FDA Law Blog) (GenericsWeb)

Mirapex (Pramipexole) – US: Mirapex case ends, Mylan Found to infringe Boehringer patent (Patent Docs)

Moviprep (Polyethylene glycol) – US: Salix settles with Novel over Moviprep (IPBiz)

Norvir (Ritonavir) – US: PUBPAT challenges eight of Abbott’s HIV/AIDS medicine patents (IP Watch)

Strattera (Atomoxetine) – US: Eli Lilly granted 14-day injunction prohibiting production of generic Strattera: Eli Lilly & Co v Actavis Elizabeth LLC (Patent Docs) (Patent Docs)

Triaz (Benzoyl peroxide) – US: Medicis files patenting infringement complaint based on Acella’s manufacture and sale of product similar to Triaz foaming cloths (Patent Docs)

Uroxatral (Alfuzosin) – US: Aurobindo and Torrent Pharma found to infringe Sanofi-Aventis’s Uroxatral patent (Patent Docs)

Vytorin (Ezetimibe, Simvastatin) – US: Schering files patenting infringement complaints against Impax in N D California and New Jersey in response to Para IV certification (Patent Docs)